US government approves of Novartis leukemia drug

US government approves of Novartis leukemia drug
US government approves of Novartis leukemia drug

A drug to treat a life-threatening form of leukemia has gained federal approval.

Tasigna, known generically as nilotinib, won approval to treat chronic and accelerated phase Philadelphia chromosome-positive, chronic myeloid leukemia, a form of the blood cancer. FDA approval is specifically for use in patients who are resistant or intolerant to previous treatment, including with another drug called Gleevec also made by the Swiss pharmaceutical company Novartis AG.